Clinical Trials Logo
  1. Home
  2. Stargardt Disease
  3. NCT06445322

Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials

Stargardt Disease Clinical Trial

Official title:
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials

Clinical Trial Summary

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Clinical Trial Description

The prescreening process will be used to help determine the initial eligibility and interest of potential participants in ACDN-01 clinical trials by conducting assessments of key eligibility criteria before the clinical trial screening procedures are performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06445322
Study type Observational
Source Ascidian Therapeutics, Inc
Contact Associate Director, Clinical Operations
Phone 207-573-0412
Email researchtrials@ascidian-tx.com
Status Recruiting
Phase
Start date June 20, 2024
Completion date August 31, 2030
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01676766 - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease N/A
Enrolling by invitation NCT06048185 - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Recruiting NCT05674058 - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Recruiting NCT06435000 - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Completed NCT04909398 - Pupil Dynamics and Color Vision for the Detection of Eye Diseases N/A
Completed NCT02255981 - Efficacy of Acupuncture in Macular Diseases N/A
Completed NCT05266014 - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease Phase 1/Phase 2
Recruiting NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR) Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Phase 2
Completed NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease Phase 3
Terminated NCT02875704 - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Phase 2
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT02410122 - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation NCT04239625 - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) Phase 2
Recruiting NCT05956626 - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease Phase 1/Phase 2
Recruiting NCT02402660 - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2
Completed NCT01977846 - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies